Liwu Fu | Pharmacology | Best Researcher Award

Prof. Liwu Fu | Pharmacology | Best Researcher Award

Professor at Sun Yat-sen University Cancer Center, China

Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. ๐ŸŽ“ He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. ๐Ÿฅ Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. ๐Ÿ”ฌ With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.

Publication Profile

Scopus

๐ŸŽ“ Educational Background

๐Ÿ“Œ Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) ๐Ÿฅ. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research ๐Ÿ”ฌ. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine ๐Ÿงฌ. His extensive education has shaped his contributions to oncology and anticancer drug development.ย ๐ŸŽ—๏ธ

๐Ÿ’ผ Professional Experience

๐Ÿ”ฌ Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) ๐Ÿฅ. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) ๐Ÿ‡บ๐Ÿ‡ธ. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations ๐ŸŽ—๏ธ. He is also an AACR member and has contributed significantly to cancer pharmacology. ๐Ÿš€

Research Focus

Dr. Liwu Fu’s research focuses on cancer biology ๐Ÿ”ฌ, particularly in tumor immunology ๐Ÿงฌ, drug resistance mechanisms ๐Ÿ’Š, and targeted therapies ๐ŸŽฏ. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer ๐Ÿซ, colorectal cancer ๐Ÿฅ, and leukemia ๐Ÿง‘โ€โš•๏ธ. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology ๐Ÿงซ and precision medicine ๐Ÿน, making key advancements in overcoming cancer treatment resistance.

Publication Top Notes

๐Ÿ“Œ Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
๐Ÿ—“ Year: 2025 |ย  Cited by: 2 |ย  Molecular Cancer

๐Ÿ“Œ Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
๐Ÿ—“ Year: 2025 |ย Advanced Science

๐Ÿ“Œ Resistance to Antibodyโ€“Drug Conjugates: A Review
๐Ÿ—“ Year: 2025 | Acta Pharmaceutica Sinica B

๐Ÿ“Œ PBA2, a Novel Inhibitor of the ฮฒ-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
๐Ÿ—“ Year: 2024 |ย Molecular Cancer

๐Ÿ“Œ BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
๐Ÿ—“ Year: 2024 | ย Cited by: 2 | ย Cell Communication and Signaling

Conclusion

Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. ๐Ÿš€๐Ÿ†